According to a new «proof of principle» study published in Aug. 27 issue of Cancer Prevention Research, Moffitt Cancer Center researchers hope to improve pancreatic cancer survival rates
by identifying markers in the blood that can pinpoint patients with premalignant pancreatic lesions called intraductal papillary
mucinous neoplasms (IPMNs).